TheraVet SA (EPA:ALVET)

Market Cap	292.67K
Revenue (ttm)	918.32K
Net Income (ttm)	-1.51M
Shares Out	3.57M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0820
Previous Close	0.0820
Day's Range	0.0820 - 0.0820
52-Week Range	0.0632 - 1.1050
Beta	-0.50
RSI	29.02
Earnings Date	Apr 10, 2025

About TheraVet

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species speci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 7
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVET

Financial Performance

In 2023, TheraVet's revenue was 1.08 million, a decrease of -32.70% compared to the previous year's 1.60 million. Losses were -1.57 million, -32.17% less than in 2022.